Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer.

@article{Baselga2005PhaseIA,
  title={Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer.},
  author={Jos{\'e} Baselga and J 1137 Albanell and Amparo Ruiz and A{\~n}a Lluch and Pedro Gasc{\'o}n and V Guillem and Sonia Gonz{\'a}lez and S{\'i}lvia Sauleda and Irene Marim{\'o}n and Josep Tabernero and Maria T Koehler and Federico Cuesta Rojo},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2005},
  volume={23 23},
  pages={5323-33}
}
PURPOSE To evaluate the antitumor activity and pharmacodynamic/biologic effect of gefitinib 500 mg/day monotherapy in patients with previously treated, advanced breast cancer. METHODS In this phase II multicenter trial, the primary objective was assessment of the tumor response rate with gefitinib; secondary objectives included analysis of the pharmacodynamic and biologic profiles in healthy and tumor tissue. RESULTS while phosphorylation of mitogen-activated protein kinase was inhibited in… CONTINUE READING

From This Paper

Topics from this paper.
174 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 174 extracted citations

Similar Papers

Loading similar papers…